Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
08 November 2024 - 3:07PM
UK Regulatory
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 8 November 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Choi Lai Christina Law |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Member of the Board of Directors |
|
|
b) |
Initial notification/Amendment |
Amendment to company announcement no. 82 / 2024 which erroneously
stated a price of DKK 697.24 in section 4.c) |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,
type of instrument, |
ADRs
|
|
|
|
Identification code |
NVO |
|
|
b) |
Nature of the transaction |
Purchase of ADRs |
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 753.02 |
1,400 ADRs |
|
|
|
d) |
Aggregated information
|
1,400 ADRs
DKK 1,054,226.88 |
|
|
e) |
Date of the transaction |
2024-11-06 |
|
|
f) |
Place of the transaction |
New York Stock Exchange |
|
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering scientific breakthroughs,
expanding access to our medicines, and working to prevent and
ultimately cure disease. Novo Nordisk employs about 69,000 people
in 80 countries and markets its products in around 170 countries.
Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more
information, visit novonordisk.com,
Facebook, Instagram,
X, LinkedIn and
YouTube.
Contacts for further information
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656
azey@novonordisk.com
|
Frederik
Taylor Pitter (US)
+1 609 613 0568
fptr@novonordisk.com
|
Ida Schaap
Melvold
+45 3077 5649
idmg@novonordisk.com |
|
Company Announcement No 83 / 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Novo Nordisk (TG:NOV)
Historical Stock Chart
Von Dez 2023 bis Dez 2024
